Sunday, 15 November 2026European Markets

SODEXO, TELEPERFORMANCE, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Specialty Business Services Industry.

Automated market report from our archive (2020–2024), published before source-traceability. How we work

Loading stream...

(vianews) - sodexo (sw.pa) is among this list of stock assets with the highest dividend rate and return on equity on the specialty business services industry.

financial asset price forward dividend yield return on equity
sodexo (sw.pa) €100.85 3% 12.65%
teleperformance (tep.pa) €151.95 2.92% 17.54%
relx (ren.as) €37.90 1.85% 50.67%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. sodexo (sw.pa)

3% forward dividend yield and 12.65% return on equity

sodexo s.a. provides food services and facilities management services worldwide. it offers various on-site services, which includes corporate services, energy and resources, government and agencies, and other services; healthcare and seniors; and learning solutions to schools and universities. the company also provides food services comprising retail service, food delivery, and meal and food vouchers, as well as digital food ordering services; savings and purchase solutions, data and digital tools, and advisory services and client support; and work-life balance and employee experience solutions. in addition, it offers facility management services, including technical service management, assets management, building maintenance, access control, deep cleaning, energy management, space planning, project management, front-of-house services, grounds maintenance, waste management, hvac systems, mail management, commercial cleaning, workspace management, and pest control. services. the company was formerly known as sodexho alliance and changed its name to sodexo s.a. in 2008. sodexo s.a. was founded in 1966 and is headquartered in issy-les-moulineaux, france.

earnings per share

as for profitability, sodexo has a trailing twelve months eps of €3.8.

pe ratio

sodexo has a trailing twelve months price to earnings ratio of 26.54. meaning, the purchaser of the share is investing €26.54 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.65%.

moving average

sodexo's worth is below its 50-day moving average of €100.98 and above its 200-day moving average of €99.20.

yearly top and bottom value

sodexo's stock is valued at €100.85 at 16:40 est, under its 52-week high of €105.40 and way higher than its 52-week low of €80.58.

dividend yield

as stated by morningstar, inc., the next dividend payment is on dec 20, 2023, the estimated forward annual dividend rate is 3.1 and the estimated forward annual dividend yield is 3%.

more news about sodexo.

2. teleperformance (tep.pa)

2.92% forward dividend yield and 17.54% return on equity

teleperformance se, together with its subsidiaries, engages in the provision of outsourced customer and citizen experience management, and related services in france and internationally. the company operates in two segments, core services and digital integrated business services, and specialized services. the core services and digital integrated business services segment offers customer and citizen care; customer relationship operations; technical support; and technical assistance and customer acquisition services, as well as back-office solutions and integrated services, including social media content moderation services and data labeling for automation solutions; and knowledge services in the field of analytics solutions, automated systems, and artificial intelligence. the company also manages business processes, as well as provides digital platform, consulting, and data analysis services; and business process outsourcing services for government agencies. the specialized services segment provides on-line interpretation, visa application management, health management services, and accounts receivable credit management services. it also offers digital recruitment process outsourcing; consumer health management business services and related digital solutions integration; translation and interpreting services; and business process outsourcing services for government agencies in the united states. the company serves automotive, energy and utilities, insurance, public sector, technology, travel and hospitality, and banking and financial services, as well as healthcare, media, retail and e-commerce, crypto, cargo, telecom, and video games industries. teleperformance se was incorporated in 1989 and is headquartered in paris, france.

earnings per share

as for profitability, teleperformance has a trailing twelve months eps of €10.78.

pe ratio

teleperformance has a trailing twelve months price to earnings ratio of 14.1. meaning, the purchaser of the share is investing €14.1 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.54%.

revenue growth

year-on-year quarterly revenue growth grew by 0.4%, now sitting on 8.17b for the twelve trailing months.

moving average

teleperformance's worth is way above its 50-day moving average of €123.69 and higher than its 200-day moving average of €145.66.

more news about teleperformance.

3. relx (ren.as)

1.85% forward dividend yield and 50.67% return on equity

relx plc, together with its subsidiaries, provides information-based analytics and decision tools for professional and business customers in north america, europe, and internationally. it operates through four segments: risk; scientific, technical & medical; legal; and exhibitions. the risk segment offers information-based analytics and decision tools that combine public and industry specific content with technology and algorithms to assist clients in evaluating and predicting risk. the scientific, technical & medical segment provides information and analytics that help institutions and professionals to progress in science and advance healthcare. the legal segment provides legal, regulatory, and business information and analytics that help customers in decision-making, as well as increases the productivity. the exhibitions segment is involved in the business that combines face-to-face with data and digital tools to help customers learn about markets, source products, and complete transactions. the company was formerly known as reed elsevier plc and changed its name to relx plc in july 2015. relx plc was incorporated in 1903 and is headquartered in london, the united kingdom.

earnings per share

as for profitability, relx has a trailing twelve months eps of €1.06.

pe ratio

relx has a trailing twelve months price to earnings ratio of 35.75. meaning, the purchaser of the share is investing €35.75 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 50.67%.

yearly top and bottom value

relx's stock is valued at €37.90 at 16:40 est, higher than its 52-week high of €37.20.

moving average

relx's value is way higher than its 50-day moving average of €34.15 and way higher than its 200-day moving average of €31.00.

revenue growth

year-on-year quarterly revenue growth grew by 13.4%, now sitting on 9.08b for the twelve trailing months.

volatility

relx's last week, last month's, and last quarter's current intraday variation average was 0.57%, 0.38%, and 0.76%.

relx's highest amplitude of average volatility was 0.57% (last week), 0.73% (last month), and 0.76% (last quarter).

more news about relx.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,580 source documents archived
Query this data → isubstrate.com